Literature DB >> 12445271

Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains.

Anne B Vogt1, Sebastian Spindeldreher, Harald Kropshofer.   

Abstract

Protein reorganization at the interface of a T cell and an antigen-presenting cell (APC) plays an important role in T cell activation. Imaging techniques reveal that reorganization of particular receptor-ligand pairs gives rise to an intercellular junction, termed the immunological synapse. In this synapse antigenic peptides associated with major histocompatibility complex (MHC) molecules form multimolecular arrays on the APC side, engaging an equivalent number of clustered T cell receptors (TCRs) on the T cell. The accumulation of MHC molecules carrying cognate peptide in the APC-T cell interface was thought to depend on the specificity and presence of TCRs. Recent evidence, however, suggests that the APC is equipped to preorganize MHC-peptide complexes in the absence of T cells. To this end, MHC molecules become incorporated into two types of membrane microdomains: (i) cholesterol- and glycosphingolipid-enriched domains, denoted lipid rafts, that preconcentrate MHC class II molecules; and (ii) microdomains made up of tetraspan proteins, such as CD9, CD63, CD81 or CD82, that mediate enrichment of MHC class II molecules loaded with a select set of peptides. It follows that the integrity, composition and dynamics of these microdomains are candidate determinants favoring activation or silencing of T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445271     DOI: 10.1034/j.1600-065x.2002.18912.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  32 in total

1.  Complete predicted three-dimensional structure of the facilitator transmembrane protein and hepatitis C virus receptor CD81: conserved and variable structural domains in the tetraspanin superfamily.

Authors:  Michel Seigneuret
Journal:  Biophys J       Date:  2006-01-01       Impact factor: 4.033

Review 2.  Why is delta endocytosis required for effective activation of notch?

Authors:  Ajay Chitnis
Journal:  Dev Dyn       Date:  2006-04       Impact factor: 3.780

Review 3.  MHC class II transport at a glance.

Authors:  Adam C Berger; Paul A Roche
Journal:  J Cell Sci       Date:  2009-01-01       Impact factor: 5.285

4.  Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Curr Transplant Rep       Date:  2015-05-24

5.  Recruitment of CD63 to Cryptococcus neoformans phagosomes requires acidification.

Authors:  Katerina Artavanis-Tsakonas; J Christopher Love; Hidde L Ploegh; Jatin M Vyas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

Review 6.  Mechanosensing in the immune response.

Authors:  Arpita Upadhyaya
Journal:  Semin Cell Dev Biol       Date:  2017-08-19       Impact factor: 7.727

7.  Annexin 2: a novel human immunodeficiency virus type 1 Gag binding protein involved in replication in monocyte-derived macrophages.

Authors:  Elena V Ryzhova; Robin M Vos; Andrew V Albright; Alexia V Harrist; Thomas Harvey; Francisco González-Scarano
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 8.  Nanoengineering approaches to the design of artificial antigen-presenting cells.

Authors:  Joel C Sunshine; Jordan J Green
Journal:  Nanomedicine (Lond)       Date:  2013-07       Impact factor: 5.307

9.  Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1

Authors:  Stephanie N Hurwitz; Mujeeb R Cheerathodi; Dingani Nkosi; Sara B York; David G Meckes
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

10.  Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.